Rankings
▼
Calendar
URGN Q2 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$927M
Q2 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$17M
+27.4% YoY
Gross Profit
$15M
88.9% margin
Operating Income
-$19M
-112.7% margin
Net Income
-$27M
-160.8% margin
EPS (Diluted)
$-1.18
QoQ Revenue Growth
+22.4%
Cash Flow
Operating Cash Flow
-$23M
Free Cash Flow
-$23M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$146M
Total Liabilities
$187M
Stockholders' Equity
-$41M
Cash & Equivalents
$81M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$17M
$13M
+27.4%
Gross Profit
$15M
$12M
+27.2%
Operating Income
-$19M
-$23M
+18.0%
Net Income
-$27M
-$26M
-1.8%
Revenue Segments
Jelmyto
$17M
100%
← FY 2022
All Quarters
Q3 2022 →